IGMM

  • Français
  • English
close

News

R2TP and R2SP are co-chaperones involved in the assembly of macro-molecular complexes

In a Nature Communications publication, Chloé Maurizy and colleagues (E. Bertrand’s team and 3 other teams from ANR consortium snoRNPASSEMBLY) have discovered a novel co-chaperone, called R2SP. It was known that macromolecular complex assembly requires dedicated machinery working with Hsp90. We and others have shown that R2TP/Hsp90 is involved in assembly of essential complexes such as snoRNPs, snRNPs, RNA polymerases … Continue reading R2TP and R2SP are co-chaperones involved in the assembly of macro-molecular complexes

Neutrophils are essential for induction of vaccine-like effects by antiviral monoclonal antibody immunotherapies.

Monoclonal antibodies (mAbs) are the largest class of biomedicines. Administered to neutralize and eliminate pathogens, they can also induce a lasting immune response, such as vaccination. The work of Mar Naranjo-Gomez et al., In the team “Oncogenesis and Immunotherapy” has demonstrated an unexpected role of a type of leukocytes, neutrophils, in the therapeutic efficacy of mAbs. These cells of the … Continue reading Neutrophils are essential for induction of vaccine-like effects by antiviral monoclonal antibody immunotherapies.

Targeting SUMO to improve the efficiency of differentiation therapies in Acute Myeloid Leukemias

Acute Myeloid Leukemias (AML) are very aggressive hematological malignancies, which treatment is mostly based on intensive chemotherapies. This treatment has not significantly changed in the past 40 years and is characterized by a high relapse rate. Differentiation therapies, in particular those using all-trans retinoic acid (ATRA) are an alternative to chemotherapies. They aim at restoring the differentiation of AML cells … Continue reading Targeting SUMO to improve the efficiency of differentiation therapies in Acute Myeloid Leukemias

Marc Sitbon is a MUSE laureate for TheranosMet.

TheranosMet is one of the 8 laureates in Biology & Health of the first call for research projects by MUSE (Montpellier Université d’Excellence). The 3-year MUSE program includes support for a PhD student. TheranosMet focuses on the theranostic use of RBD nanoparticles. RBDs are Receptor-Binding Domains derived from retroviruses that target nutrient transporters. RBDs that bind transporters known to play … Continue reading Marc Sitbon is a MUSE laureate for TheranosMet.

Probing instructions for expression regulation in gene nucleotide compositions.

Identifying a maximum of DNA determinants implicated in gene regulation will accelerate genetic analyses and precision medicine approaches by identifying key gene features. In that context decoding the sequence-level instructions for gene regulation is of prime importance. Among global efforts to achieve this objective, we propose a novel approach able to explain gene expression in each patient sample using only … Continue reading Probing instructions for expression regulation in gene nucleotide compositions.

Why low doses of anticancer drugs may be more effective ?

[ Article in French ]
Les équipes de Daniel Fisher à l’Institut de génétique moléculaire de Montpellier et de Michael Hochberg à l’Institut de sciences de l’évolution de Montpellier, apportent la première validation expérimentale du concept de la “Thérapie Adaptative” fondée sur les principes de l’évolution Darwinienne. Cette stratégie thérapeutique émergente repose sur l’idée, non encore validée, que l’administration de doses réduites d’anticancéreux qui arrêtent la prolifération des cellules cancéreuses, pourrait se révéler plus efficace en maintenant une compétition entre cellules sensibles et résistantes à la chimiothérapie.